Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11102704 | 0.88 | HRH4 (0.41) | PRKD1PRKD2MAPK14KARS1HRH4 | |
| SCHEMBL11100755 | 0.84 | MAPK14 (0.47) | PRKD1PRKD2MAPK14MAPK13MAPK12 | |
| SCHEMBL11102425 | 0.83 | ROCK1 (0.44) | PRKD1MAPTKARS1ROCK2ROCK1 | |
| SCHEMBL11100753 | 0.81 | MAPK14 (0.40) | PRKD1PRKD2MAPK14MAPK10 | |
| SCHEMBL11098688 | 0.81 | PRKD1 (0.48) | PRKD1PRKD2MAPK14MAPK13MAPK12 | |
| SCHEMBL11101994 | 0.80 | MAPK10 (0.32) | PRKD1PRKD2KARS1PLK1MAPK10 | |
| SCHEMBL11101947 | 0.80 | NOS2 (0.54) | PRKD2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25095006 | 0.80 | MAPK10 (0.33) | MAPK14MAPTROCK2ROCK1MAPK10 | |
| SCHEMBL11099057 | 0.79 | PRKD1 (0.45) | PRKD1PRKD2MAPK14MAPK13MAPK12 | |
| SCHEMBL11103308 | 0.79 | PRKD1 (0.45) | PRKD1PRKD2MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | claimed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | claimed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | claimed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| CN-102083429-B | Ido inhibitors | NEWLINK GENETICS | 2014-05-28 | — | — | CN | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-0051371-B1 | IMIDAZOLYLPYRIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0051371-A2 | Imidazolylpyridine therapeutic agents | PFIZER INC. (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4302464-A | ANTIULCER AGENTS, ANTI-H2-HISTAMINES | PFIZER INC. (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | PRKD1 3921/4885PRKD2 3250/4885MAPK14 3740/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | PRKD1 3921/4885PRKD2 3250/4885MAPK14 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.